Business Wire

iFIT Inc. Partners with World Champion Olli Zeidler as Brand Ambassador and iFIT Trainer

19.8.2025 15:00:00 CEST | Business Wire | Press Release

Share

iFIT Inc., a global leader in connected fitness and interactive content, proudly announces a new global ambassadorship with elite German rower and Olympic champion Oliver Zeidler. This announcement coincides with NordicTrack’s 50th anniversary celebration, as the brand continues its mission to deliver immersive, science-backed fitness experiences that empower athletes across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819418453/en/

The German powerhouse athlete will be joining the iFIT platform as its newest trainer and will be prominently featured in the company’s marketing throughout Europe.

Zeidler, a standout in international rowing, captured gold in the men’s single sculls at the 2024 Paris Olympics—Germany’s first in the event since 1992. In addition to multiple World and European Championship titles, he was named Germany’s Sportsperson of the Year in 2024, a testament to his dominance and stature in elite sport. He transitioned from swimming to rowing in 2016—a challenging move that showcased his mental resilience and determination to start over and excel. It's the kind of inner strength iFIT values just as much as physical performance.

"Joining the iFIT team is a natural fit for me,” says Zeidler. “iFIT is all about pushing physical, mental, and personal boundaries, which is exactly how I’ve approached my journey in sport and in life. I’m excited to bring my experience and passion to this incredible global community and to help inspire others to chase their own version of excellence."

In addition to his athletic achievements, Zeidler holds a Master of Laws in Taxation and has worked as a consultant with Deloitte Germany, balancing a demanding professional career with world-class training. He is currently pursuing his Masters in Business Administration at IMD Business School in Lausanne, Switzerland.

Now based in Lausanne, Switzerland, home of the International Olympic Committee, Zeidler is preparing for the 2028 Los Angeles Olympics. To launch his partnership with iFIT, Zeidler hosted the brand in his hometown, where exclusive content for an upcoming campaign was filmed.

“Olli embodies the kind of performance, character, and story that resonates deeply with our global audience,” said Kirsten Spittel-Sloan, Global Head of Marketing at iFIT Inc. “He’s not just an elite athlete—he’s a symbol of what it means to commit, evolve, and achieve. We are proud to welcome him to the iFIT family.”

About iFIT Inc.

iFIT Inc. is a global leader in fitness technology, pioneering connected fitness to help people live longer, healthier lives. With a community of more than 6 million athletes around the world, iFIT delivers immersive, personalized workout experiences at-home, on the go, and in the gym. Powered by a comprehensive ecosystem of proprietary software, innovative hardware, and engaging content, the iFIT platform brings fitness to life through its portfolio of brands: NordicTrack, ProForm, Freemotion, and the iFIT app. From cardio and strength training to recovery, iFIT empowers athletes at every stage of their fitness journey. For more information, visit iFIT.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250819418453/en/

Contacts

For media inquiries or partnership details, please contact:
Edelman for iFIT Inc.
iFIT@edelman.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye